Alpha Tau Medical Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of May 2026, specifically dated May 11, 2026. Alpha Tau Medical Ltd., a foreign private issuer, filed this report to disclose the presentation of interim clinical data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), known as the REGAIN trial. The data was presented during a conference call and webcast on May 11, 2026, and is attached as Exhibit 99.1.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or quantitative financial metrics.
Material Changes
The material change disclosed is the release of interim clinical data from the REGAIN trial. The filing does not compare this event to a prior comparable period in terms of financial performance or operational metrics.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical data presentation. The filing explicitly states that the Company does not undertake any obligation to update the presentation or forward-looking statements to reflect subsequent actual results. The information is furnished and not deemed "filed" under Section 18 of the Exchange Act, limiting liability for the content. No specific risks, contingencies, or unusual items are detailed in the text of this filing.
Key Facts for Investor Verification
- Verify the specific interim clinical data results for the REGAIN trial in the attached Exhibit 99.1 presentation.
- Confirm the status of the Alpha DaRT therapy for recurrent glioblastoma based on the May 11, 2026, conference call.
- Note that this filing does not contain updated financial statements or forward-looking guidance obligations.